RxDoctor Payments Data

Kimberly Yeager

Sleep Medicine · Reno, NVNPI 1194874214

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,480 of the $3,865 with a category attached, or 64.2%. Inspire Medical Systems, Inc. accounts for 74.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $2,857 and has fallen 92.3% since, to $221 in 2025.

$3,865in general payments, 2019–2025

Across 65 payments — averaging $59.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$3K
  • AstraZeneca$330
  • Jazz Pharmaceuticals Inc.$248
  • GSK$152
  • Lilly USA, LLC$62
  • Baxter Healthcare$57
  • plus $156 from 6 others

What the payments were for

  • Travel & lodging$1,24832%
  • Food & beverage$2,48064%
  • Education$1384%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few sleep medicine providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$122,481
Medicare patients
364
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant13$7,977
Zolpidem Tartrate55$44

Paid to pharmacies, not to this prescriber.

Other sleep medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →